DUX4L16

Across TCGA pan-cancer cohorts, DUX4L16 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated DUX4L16 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher DUX4L16 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated DUX4L16 expression acts as an unfavorable survival marker.

STAD, SKCM, and THYM are the cancer types where DUX4L16 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	III,IV	0.205	0.648	.002	39	view →
SKCM	DFS	Tertile	IV	0.036	0.433	<.001	18	view →
THYM	DFS	Tertile	II,III,IV	0.185	0.747	.019	18	view →
ESCA	OS	Tertile	II,III,IV	0.262	0.557	.016	18	view →
BRCA	DFS	Tertile	II,III,IV	0.858	0.944	.017	12	view →
UVM	DFS	Tertile	III,IV	0.071	0.636	<.001	9	view →
PCPG	OS	Tertile	All	0.810	0.974	.040	9	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DUX4L16–STAD (OS)

Open the STAD breakdown →